|
|
Please type responses here: |
|
First Name:
|
|
|
Last Name:
|
|
|
Email Address:
|
|
|
Retype Email Address:
|
|
|
Title:
|
|
|
Institution:
|
|
|
Phone Number:
|
|
|
City:
|
|
|
State/Province:
|
|
|
Postal/Zip Code:
|
|
|
Country:
|
|
|
What topics would you like to see covered in future POC Group Webinars?
|
|
|
Overall, how would you rate your satisfaction with this Point of Care Web Meeting?
|
Extremely satisfied
Very satisfied
Somewhat satisfied
Dissatisfied
|
|
Your feedback helps your webinar producers and sponsors improve the overall quality of their products and services.
|
|
I would like to know more about (choose all that apply):
|
Adding a device type to RALS
Knowing more about operator management tools
Scalable feature sets
The Configurable Device Driver tool
|
|
What current data management system(s) are you using? Choose all that apply:
|
Abbott PrecisionWeb™
GEMweb® Plus
Orchard® Point-of-Care
Radiometer AQURE
Radiometer Radiance
RALS™ Connectivity System
Roche cobas® IT 1000 / cobas® infinity POC
SIEMENS POCcelerator™
SIEMENS RapidComm®
SIEMENS UniPOC™
Telcor QML®
None
Other
|
|
If you chose ‘other’ in the question above, please list your current data management system(s):
|
|
|
Do you currently use Cepheid tests?
|
Yes
No
|
|
Are you looking to add any new CLIA waived molecular tests this year?
|
Yes
No
|
|
Would you like to be contacted to learn more about Cepheid's POC solutions?
|
Yes
No
|
|
Which of the following best describes natriuretic peptide (BNP or NT-proBNP) testing in your health system?
|
Currently offer point of care natriuretic peptide tests in our hospital setting
Currently offer point of care natriuretic peptide tests in our outpatient clinics
Currently offer point of care natriuretic peptide tests in both outpatient clinics and hospital setting
None, this is offered as a send-out test or run in the lab not POC
N/A – I don’t oversee POC tests outside of the hospital
|
|
Are you open to learning more about how the LumiraDx Platform and microfluidic test technology might fit into your decentralized lab settings?
|
Yes
No
N/A
|
|
What type of point of care tests do you currently utilize? Please check all that apply:
|
Diabetes monitoring (HbA1c)
Lipid Panel
COVID-19
Flu
Strep
Drugs of Abuse
Other
I do not do point of care testing
|
|
Would you like to know more about Abbott’s HbA1c and cholesterol point of care testing offerings?
|
Yes – Both HbA1c and Cholesterol Testing
Yes- HbA1c only
Yes- Cholesterol only
No
Not Sure
|
|
Does your POCT program include troponin testing?
|
Yes
No
|
|
Are you able to utilize your existing POCT middleware system to connect ambulatory offices and other off-campus testing sites?
|
Yes
No
|
|
Would you like to receive ASCLS PACE credit for this session, program number 174-017-24? (If no, you do not need to complete the following questions.)
|
Yes
No
|
|
To receive ASCLS PACE credit (PACE Program number 174-017-24, California Agency #0001) for "Point of Care Troponin Testing: Current Status and Future Promise" presented on September 10, 2024, you will be required to complete the following program evaluation.
|
|
If the following is true, please answer "Yes": I have attended the full instructional time for this program. I understand that completion of the program is necessary to receive the contact hours awarded for the program.
|
Yes
No
|
|
SPEAKER RATING
|
|
To what extent was the speaker knowledgeable, organized and effective during the presentation? (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
To what extent did the speaker clarify and focus on the stated objectives? (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
To what extent were the speaker's teaching methods & aids appropriate & effective? (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
OBJECTIVES RATING:
To what extent was each objective achieved?
|
|
List the biomarker criteria needed to establish the diagnosis of myocardial infarction. (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
Sketch the rise of cardiac troponin after MI and explain basis for rapid rule-out of MI. (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
Explain the definition of early generation, contemporary and high-sensitivity cardiac troponin assays. (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
Discuss how use of POC assays an aid in improving the efficiency and effectiveness of high-sensitivity cardiac troponin in urgent care. (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
PROGRAM CONTENT RATING
|
|
To what extent did the program content relate to the program's objectives? (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
Rate the contribution of this session to your overall knowledge of this subject. (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
Rate your overall degree of satisfaction with this session. (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
Comments:
|
|
|
Thank you for attending this PACE approved program and completing this evaluation. Questions? Call Whitehat Communications at 434 202 8365.
|
|
|
